Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -98.56% is 73% below its 5-year average of -57.03%, near the low end of its 5-year range (-115.80%–-26.36%).
As of the fiscal period ended Tuesday, June 30, 2026. 48.55% below its 12-month average of -66.35%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -98.56%.
RETURN ON EQUITY (ROE)
-98.56%
RETURN ON EQUITY (ROE) AVG TTM
-66.35%
RETURN ON EQUITY (ROE) AVG 3Y
-57.76%
RETURN ON EQUITY (ROE) AVG 5Y
-57.03%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-48.55%
CURRENT VS 3Y AVG
-70.65%
CURRENT VS 5Y AVG
-72.83%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-134.62%
vs the sector median at left
Vera Therapeutics, Inc.
Market Cap
$2.11B
Return on Equity (ROE)
-98.56%
TTM Avg
-66.35%
3Y Avg
-57.76%
5Y Avg
-57.03%
Market Cap
$2.11B
Return on Equity (ROE)
9.17%
TTM Avg
8.21%
3Y Avg
8.13%
5Y Avg
7.80%
Market Cap
$2.11B
Return on Equity (ROE)
-23.58%
TTM Avg
-182.08%
3Y Avg
-186.85%
5Y Avg
-151.51%
Market Cap
$2.13B
Return on Equity (ROE)
-43.55%
TTM Avg
-14.07%
3Y Avg
-80.41%
5Y Avg
-980.81%
Market Cap
$2.06B
Return on Equity (ROE)
-58.45%
TTM Avg
-43.81%
3Y Avg
-43.57%
5Y Avg
-51.47%
Market Cap
$2.06B
Return on Equity (ROE)
-42.07%
TTM Avg
-35.11%
3Y Avg
-34.40%
5Y Avg
-30.49%
Market Cap
$2.17B
Return on Equity (ROE)
-37.82%
TTM Avg
-53.05%
3Y Avg
-23.57%
5Y Avg
8.38%
Market Cap
$2.05B
Return on Equity (ROE)
6.55%
TTM Avg
4.11%
3Y Avg
-0.47%
5Y Avg
-0.69%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Vera Therapeutics, Inc. (VERA) | $2.11B | -98.56% | -66.35% | -57.76% | -57.03% |
| Addus HomeCare Corporation (ADUS)vs › | $2.11B | 9.17% | 8.21% | 8.13% | 7.80% |
| SELLAS Life Sciences Group, Inc. (SLS)vs › | $2.11B | -23.58% | -182.08% | -186.85% | -151.51% |
| GeneDx Holdings Corp. (WGS)vs › | $2.13B | -43.55% | -14.07% | -80.41% | -980.81% |
| Alvotech (ALVO)vs › | $2.08B | N/A | 23.18% | 49.13% | 48.50% |
| Viridian Therapeutics, Inc. (VRDN)vs › | $2.06B | -58.45% | -43.81% | -43.57% | -51.47% |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.06B | -42.07% | -35.11% | -34.40% | -30.49% |
| Maravai LifeSciences Holdings, Inc. (MRVI)vs › | $2.17B | -37.82% | -53.05% | -23.57% | 8.38% |
| Vericel Corporation (VCEL)vs › | $2.05B | 6.55% | 4.11% | -0.47% | -0.69% |
| Pharvaris N.V. (PHVS)vs › | $2.17B | -57.96% | -57.45% | -48.08% | -40.68% |
ROE
-98.6%
ROA
-75.4%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -98.56% |
| 2026-03-31 | -73.84% |
| 2025-12-31 | -49.56% |
| 2025-09-30 | -63.16% |
| 2025-06-30 | -46.61% |
| 2025-03-31 | -32.80% |
| 2024-12-31 | -26.36% |
| 2024-09-30 | -46.49% |
| 2024-06-30 | -32.89% |
| 2024-03-31 | -26.67% |
| 2023-12-31 | -94.40% |
| 2023-09-30 | -83.08% |
| 2023-06-30 | -76.39% |
| 2023-03-31 | -64.70% |
| 2022-12-31 | -115.80% |
| 2022-09-30 | -69.49% |
| 2022-06-30 | -46.41% |
| 2022-03-31 | -33.46% |
| 2021-12-31 | -46.86% |
| 2021-09-30 | -68.60% |
| 2021-06-30 | -60.21% |
